Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Gift or transfer — classified separately from trades.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 12, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 16, 2026
CEOGift / transfer
Context
Classification
gift transfer
Code G — gift, bequest or transfer
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001213900-26-028291
Filed / recorded
Mar 16, 2026, 8:06 PM UTC
Added to OQRO
Oct 8, 2026, 1:45 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ORAMED PHARMACEUTICALS INC.
Issuer CIK
1176309
Ticker
ORMP
Reporting person
Nadav Kidron
Relationship
Director, Officer
Officer title
President and CEO
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Mar 12, 2026
Transaction code
G
Shares / units
100,000
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
3,255,238
Ownership form
Direct
Amendment
No
Footnotes from the filing
This transaction represents a charitable donation and is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.